Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Blood (2024) 144 (Supplement 1): 584.

https://doi.org/10.1182/blood-2024-194593

Published: 2024

Journal Articles

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Blood (2023) 142 (Supplement 1): 3268.

https://doi.org/10.1182/blood-2023-173341

Published: 2023

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

Impact of High Body Surface Area on AML Outcome in Younger Patients: A Goelams Study

Xavier Cahu, MD, Martin Carre, MD, Christian Recher, MD, Emmanuel Gyan, MD PhD, Jean-Francois Hamel, Arnaud Pigneux, MD PhD, Norbert Vey, MD PhD, Philippe Guardiola, MD, Jacques Delaunay, MD, Eric Jourdan, MD PhD, Bruno Lioure, Marie-Christine Bene, MD, Norbert Ifrah, Jean-Yves Cahn

Blood (2014) 124 (21): 973.

https://doi.org/10.1182/blood.V124.21.973.973

Published: 2014

Journal Articles

Modeling Growth Of Pediatric T-ALL In Vivo and In Vitro : Clinical Meaning and Activation Of The NFkB Pathway

Sandrine Poglio, PhD, Xavier Cahu, MD, Benjamin Uzan, PhD, Hélène Lapillonne, MD, Thierry Leblanc, MD, André Baruchel, MD, Judith Landman-Parker, MD, PhD, Arnaud Petit, MD, Frederic Baleydier, MD, PhD, Sophie Amsellem, PhD, Paola Ballerini, MD, PhD, Françoise Pflumio, PhD

Blood (2013) 122 (21): 2571.

https://doi.org/10.1182/blood.V122.21.2571.2571

Published: 2013

Journal Articles

Prolonged Fluconazole Prophylaxis Is Not Required In Patients With Acute Leukemias Or Myelodysplastic/Myeloproliferative Disorders After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): A Pair-Matched Analysis

Eolia Brissot, MD, Xavier Cahu, MD, Thierry Guillaume, MD, Jacques Delaunay, MD, Sameh Ayari, Cristina Precupanu, MD PhD, Pierre Peterlin, Jean-Luc Harousseau, MD, Noel Milpied, MD, PhD, Philippe Moreau, MD, Mohamad Mohty, MD, PhD, Patrice Chevallier, MD, PhD

Blood (2013) 122 (21): 4543.

https://doi.org/10.1182/blood.V122.21.4543.4543

Published: 2013

Journal Articles

Allogeneic Stem Cell Transplantation In Philadelphia Negative Myeloproliferative Or Myelodysplastic/Myeloproliferative Neoplasms: A Retrospective Analysis From The Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

Xavier Cahu, MD, Patrice Chevallier, MD, PhD, Aline Clavert, MD, Felipe Suarez, MD, PhD, Mauricette Michallet, MD, Nathalie Fegueux, MD, Stephane Vigouroux, MD, Didier Blaise, Gérard Socié, MD, PhD, Clara Mariette, Karin Bilger, MD, Ibrahim Yakoub-Agha, MD, PhD, Regis Peffault de Latour, Mohamad Mohty, MD, PhD

Blood (2013) 122 (21): 3373.

https://doi.org/10.1182/blood.V122.21.3373.3373

Published: 2013

Journal Articles

Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with T-Cell Acute Lymphoblastic Leukemia: A Survey From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Xavier Cahu, MD, Myriam Labopin, Sebastian Giebel, MD, Gerard Socie, MD, Pr, Dietrich Beelen, Renate Arnold, MD, Mauricette Michallet, MD, PhD, Noel Milpied, MD, Gulsan Sucak, Gunhan Gurman, MD, Slawomira Kyrcz-Krzemien, MD, PhD, Jakob R. Passweg, Ibrahim Yakoub-Agha, MD, PhD, Matthias Stelljes, MD, Jordi Esteve, MD, PhD, Mohamad Mohty, MD, PhD

Blood (2012) 120 (21): 356.

https://doi.org/10.1182/blood.V120.21.356.356

Published: 2012

Journal Articles

Whole Blood Transcriptional Profiling of DLBCL At Diagnosis: Evidence of Systemic Changes Altering T-Cell Signaling Pathways

Delphine Rossille, PhD, Céline Pangault, PharmD, PhD, Xavier Cahu, MD, Thierry Lamy, MD, PhD, Burgun Anita, MD, PhD, Noel Milpied, MD, Thierry Fest, MD, PhD

Blood (2011) 118 (21): 2435.

https://doi.org/10.1182/blood.V118.21.2435.2435

Published: 2011

Journal Articles

Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT),

Aline Clavert, MD, Peric Zina, MD, Xavier Cahu, MD, Patrice Chevallier, MD, Eolia Brissot, Florent Malard, Thierry Guillaume, Jacques Delaunay, MD, Sameh Ayari, Viviane Dubruille, Beatrice Mahe, Nicolas Blin, MD, Thomas Gastinne, Virginie Roland, Steven Le Gouill, MD, PhD, Jean-Luc Harousseau, Philippe Moreau, MD, Noel Milpied, MD, Mohamad Mohty

Blood (2011) 118 (21): 4100.

https://doi.org/10.1182/blood.V118.21.4100.4100

Published: 2011

Journal Articles

Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Unrelated Umbilical Cord Blood Transplantation (UCBT)

Blood (2010) 116 (21): 2334.

https://doi.org/10.1182/blood.V116.21.2334.2334

Published: 2010

Journal Articles

Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2010) 116 (21): 1259.

https://doi.org/10.1182/blood.V116.21.1259.1259

Published: 2010

Journal Articles

Infectious Complications After Unrelated Umbilical Cord Blood Transplantation (UCBT) in Adult Patients with Hematological Malignancies.

Xavier Cahu, Fanny Rialland, Cyrille Touzeau, Patrice Chevallier, MD, Thierry Guillaume, Jacques Delaunay, Sameh Ayari, Viviane Dubruille, Steven Le Gouill, MD, PhD, Beatrice Mahe, Thomas Gastinne, Nicolas Blin, Beatrice Saulquin, Jean-Luc Harousseau, Philippe Moreau, MD, Francoise Mechinaud, Mohamad Mohty, MD, PhD

Blood (2009) 114 (22): 1142.

https://doi.org/10.1182/blood.V114.22.1142.1142

Published: 2009

Journal Articles

Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography ([ 18 F] FDG-PET/CT) in Aggressive T-Cell Lymphomas

Xavier Cahu, Caroline Bodet-Milin, Thomas Gastinne, Hervé Maisonneuve, Nadine Morineau, Gandhi Damaj, Philippe Solal-Celigny, Philippe Moreau, Henri Jardel, Philippe Moreau, Jean-Luc Harousseau, Françoise Kraeber-Bodéré, Steven Le Gouill, MD, PhD

Blood (2008) 112 (11): 2835.

https://doi.org/10.1182/blood.V112.11.2835.2835

Published: 2008

Journal Articles

Prior High Dose Chemotherapy and a Higher “Intensity” of the Preparative Regimen Can Influence Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).

Mohamad Mohty, MD, PhD, Xavier Cahu, Catherine Faucher, MD, Patrice Chevallier, MD, Norbert Vey, MD, Jean El-Cheikh, MD, Thierry Guillaume, MD, Sabine Furst, MD, Jacques Delaunay, MD, Hugues de Lavallade, MD, Philippe Moreau, MD, Jean-Albert Gastaut, MD, Jean-Luc Harousseau, MD, Didier Blaise, MD

Blood (2007) 110 (11): 2001.

https://doi.org/10.1182/blood.V110.11.2001.2001

Published: 2007

NARROW

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Final Results of the Eradic Trial from the Filo Group

Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Impact of High Body Surface Area on AML Outcome in Younger Patients: A Goelams Study

Modeling Growth Of Pediatric T-ALL In Vivo and In Vitro : Clinical Meaning and Activation Of The NFkB Pathway

Prolonged Fluconazole Prophylaxis Is Not Required In Patients With Acute Leukemias Or Myelodysplastic/Myeloproliferative Disorders After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): A Pair-Matched Analysis

Allogeneic Stem Cell Transplantation In Philadelphia Negative Myeloproliferative Or Myelodysplastic/Myeloproliferative Neoplasms: A Retrospective Analysis From The Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients with T-Cell Acute Lymphoblastic Leukemia: A Survey From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)

Whole Blood Transcriptional Profiling of DLBCL At Diagnosis: Evidence of Systemic Changes Altering T-Cell Signaling Pathways

Long-Term Complications (LTC) and Quality of Life (QOL) After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT),

Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Unrelated Umbilical Cord Blood Transplantation (UCBT)

Epstein Barr Virus (EBV) Reactivation After Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplantation

Infectious Complications After Unrelated Umbilical Cord Blood Transplantation (UCBT) in Adult Patients with Hematological Malignancies.

Interest and Prognosis Value of Fluorine-18-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography ([ 18 F] FDG-PET/CT) in Aggressive T-Cell Lymphomas

Prior High Dose Chemotherapy and a Higher “Intensity” of the Preparative Regimen Can Influence Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only